Clinical trial

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

NCT04053322

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Durvalumab Normalized identity: durvalumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Olaparib Normalized identity: olaparibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrantView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2019-08-26

PhasePHASE2

Conditions

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancerunresolved

a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Statusunresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

OlaparibDRUG · verified · RxNorm: olaparib

FulvestrantDRUG · verified · RxNorm: fulvestrant

Sponsors & collaborators

UNICANCERlead sponsor

ARCAGY/ GINECO GROUPcollaborator

SOLTI Breast Cancer Research Groupcollaborator

Mapped research locations

MontpellierFrance1 RouenFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04053322 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.